List of Treanda drug patents

Treanda is owned by Cephalon.

Treanda contains Bendamustine Hydrochloride.

Treanda has a total of 18 drug patents out of which 0 drug patents have expired.

Treanda was authorised for market use on 20 March, 2008.

Treanda is available in solution;iv (infusion), powder;iv (infusion) dosage forms.

Treanda can be used as for use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl), for use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; for use in the treatment of patients with chronic lymphocytic leukemia (cll), for use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma.

The generics of Treanda are possible to be released after 26 April, 2031.

TREANDA's oppositions filed in EPO
TREANDA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445524 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895756 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8609863 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8791270 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8609863

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(3 years from now)

US8791270

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(3 years from now)

US8895756

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(3 years from now)

US8883836 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

US9533955 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

US8669279 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

US8344006 CEPHALON Liquid formulations of bendamustine
Sep, 2029

(6 years from now)

US9533955

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(6 years from now)

US8883836

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(6 years from now)

US8669279

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(6 years from now)

US8445524

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(6 years from now)

US8344006

(Pediatric)

CEPHALON Liquid formulations of bendamustine
Mar, 2030

(7 years from now)

US8436190 CEPHALON Bendamustine pharmaceutical compositions
Oct, 2030

(7 years from now)

US8436190

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
ODE* (ODE*) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 March, 2008

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll)

Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)

How can I launch a generic of TREANDA before it's patent expiration?
More Information on Dosage

TREANDA family patents

37

United States

7

China

6

Australia

6

European Union

5

Japan

4

Mexico

4

Korea, Republic of

3

Hong Kong

3

Canada

2

Spain

2

Argentina

2

Taiwan, Province of China

1

Singapore

1

Malaysia

1

Brazil

1

New Zealand

1

Norway

1

EA

1

South Africa

1

Ukraine

1

Chile

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic